Clinical Trial Update: Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating nicotinamide riboside with and without resveratrol to improve functioning in peripheral artery disease has completed and poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Artery Disease

Drugs mentioned

• Nicotinamide Riboside (Niagen) (Nicotinamide riboside)
• Resveratrol (resveratrol)

Snippet

Sponsor: Northwestern University | Conditions: Peripheral Artery Disease | Phase 3 | Status: COMPLETED | Results posted: 2025-01-14